

**FSD PHARMA INC.**  
(the “Corporation”)

**CERTIFICATE**

**TO:** British Columbia Securities Commission  
Alberta Securities Commission  
Financial and Consumer Affairs Authority of Saskatchewan  
The Manitoba Securities Commission  
Ontario Securities Commission  
Financial and Consumer Services Commission, New Brunswick  
Nova Scotia Securities Commission  
Office of the Superintendent of Securities, Prince Edward Island  
Office of the Superintendent of Securities Service Newfoundland and Labrador

**RE: The abridgement of time pursuant to National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer***

---

Pursuant to subsection 2.20(c) of National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* (“**NI 54-101**”), and in connection with the annual meeting of shareholders of the Corporation to be held on June 23, 2022 (the “**Meeting**”), the undersigned, Nathan Coyle, the Chief Financial Officer of the Corporation, hereby certifies for and on behalf of the Corporation and not in his personal capacity, that the Corporation:

- (a) has arranged to have proxy-related materials for the Meeting to be sent in compliance with the applicable timing requirements in Sections 2.9 and 2.12 of NI 54-101;
- (b) has arranged to have carried out all of the requirements of NI 54-101 in addition to those described in subparagraph (a); and
- (c) is relying upon Section 2.20 of NI 54-101 in connection with the abridgement of certain of the time periods specified in NI 54-101 in respect of the Meeting.

**DATED** this 20<sup>th</sup> day of May, 2022.

**FSD PHARMA INC.**

By: “Nathan Coyle”  
Name: Nathan Coyle  
Title: Chief Financial Officer